ResultsIQ › Latest results › Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited (SHUKRAPHAR) quarterly results
NSE: SHUKRAPHAR · BSE: 524632
Shukra Pharmaceuticals Limited Q2 FY27 results
As filed: Revenue ₹44.2 cr, EBITDA ₹22.0 cr, PAT ₹16.0 cr, EBITDA margin 49.8%.
Not scored. No result for the same quarter last year.
Figures from the company's filings with NSE and BSE. Not investment advice.
About Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, including tablets, capsules and liquid injectables, in India and internationally.
What Shukra Pharmaceuticals Limited does
Manufactures and trades pharmaceutical formulations and does laboratory testing. Product portfolio includes antibiotics such as penicillin and cephalosporin, macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-ulcer, beta blockers, diuretics, analgesics, muscle relaxants, anti-tuberculosis, vitamin products, anti-allergics and corticosteroids. Has four manufacturing divisions: tablets (General and Beta Lactum), capsules (General and Beta Lactum), liquid and small volume parenteral. Was formerly known as Relish Pharmaceuticals Limited; the name changed to Shukra Pharmaceuticals Limited in August 2016.
How it makes money
- Revenue comes from manufacturing and trading of pharmaceutical formulations and from laboratory testing.
- It manufactures and markets pharmaceutical products in India and internationally.
- Revenue was ₹325.87M and net income ₹95.75M, with 2025 sales growth of -56.30%.
Customers and markets
- Customers include Cadila Healthcare Limited (Zydus), Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Makers Laboratories Limited and Agenta Pharma Limited.
- Sells in India and internationally.
Plants and capacity
- Rakanpur, Gujarat: Pharmaceutical formulations
- Medical Device Park, Greater Noida (10 acres, letter of intent from YEIDA): Advanced surgical robotics and Boron Neutron Capture Therapy (BNCT) technology, capacity Rs 600-crore facility (February 2026)
Segments
- Tablets
- Capsules
- Liquid and small volume parenteral
Key facts
- Founded: Incorporated in 1993; formerly Relish Pharmaceuticals Limited, renamed Shukra Pharmaceuticals Limited in August 2016 (2016)
- Headquarters: Veer House, 3rd Floor, Opp. WIAA Motor Training School, Judges Bunglow Road, Bodakdev, Ahmedabad, 380054, India
- Employees: 115 full-time employees
- Revenue: ₹325.87M (fiscal year-end 03/2026)
- Net income: ₹95.75M (fiscal year-end 03/2026)
- Sales growth: -56.30% (2025)
- Chairman & MD: Mr. Dakshesh Rameshchandra Shah (31 December 2025)
- CFO & Whole Time Director: Ms. Anar Jayesh Patel (31 December 2025)
What the company says sets it apart
- The company says it has fully integrated facilities for manufacturing general formulations like tablets, capsules and small volume parenteral since 2017.
- The company says it has achieved WHO-GMP certification.
- The company says it secured a partnership with Meril Healthcare for robotic surgery projects in October 2025.
- The company says it signed a memorandum of understanding with Borns Medical Robotics Inc. to bring surgical robotics technology to India.
- The company says its joint venture with Borns aims to make robotic surgery affordable and accessible in India and Asia.
The company's own claims, as stated in its filings and website.
AI-written from 8 public sources; every line links its source on the page.